Evidence map›Paper›PMID 31522249›Full record

ReviewClinical research in cardiology : official journal of the German Cardiac Society2020

Are atrial high rate episodes (AHREs) a precursor to atrial fibrillation?

Ahsan A Khan, Giuseppe Boriani, Gregory Y H Lip

Open access · hybridAbstract readReview
In one paragraph

Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. The influence of atrial high-rate episodes on stroke and cardiovascular death: an update.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  11. Article
  12. When to set anticoagulant therapy in asymptomatic AF? looking for a cut-off duration.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Article
  18. New Technologies for Detection and Management of Atrial Fibrillation.Journal of the Saudi Heart Association · 2021
    Review
  19. Article
  20. Atrial inflammation in different atrial fibrillation subtypes and its relation with clinical risk factors.Clinical research in cardiology : official journal of the German Cardiac Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Ahsan A KhanInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0003-1617-1464
Giuseppe BorianiDivision of Cardiology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico Di Modena, Modena, Italy.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX, UK. gregory.lip@liverpool.ac.uk.
University of Liverpool · GBUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial high rate episodes (AHREs), also termed, subclinical atrial tachyarrhythmias or subclinical atrial fibrillation (AF) are an important cardiovascular condition. Advancement in implantable cardiac devices such as pacemakers or internal cardiac defibrillators has enabled the continuous assessment of atrial tachyarrhythmias in patients with an atrial lead. Patients with device-detected AHREs are at an elevated risk of stroke and may have unmet anticoagulation needs. While the benefits of oral anticoagulation for stroke prevention in patients with clinical AF are well recognised, it is not known whether the same risk-benefit ratio exists for anticoagulation therapy in patients with AHREs. The occurrence and significance of AHRE are increasingly acknowledged but these events are still not often acted upon in patients presenting with stroke and TIA. Additionally, patients with AHRE show a significant risk for major adverse cardiovascular events (MACE) including acute heart failure, myocardial infarction, cardiovascular hospitalisation, ventricular tachycardia/fibrillation, which is dependent on AHRE burden. In this review, we present an overview of this relatively new entity, its associated thromboembolic risk and its management implications.

Indexed as

Heart RateAction PotentialsAdministration, OralAnticoagulantsAsymptomatic DiseasesAtrial FibrillationHeart AtriaHumansPrognosisRisk AssessmentRisk FactorsStrokeTachycardia, SupraventricularThromboembolismAnticoagulantsAnticoagulationAtrial fibrillationAtrial high rate episodesStrokeThromboembolism

Identifiers

PMID31522249
PMCPMC7098931
OpenAlexW2972704913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.